Home    Back

Vari    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
62Paroxysmal nocturnal hemoglobinuria1
274Osteogenesis Imperfecta1

62. Paroxysmal nocturnal hemoglobinuria    [ 202 clinical trials,   120 drugs,   (DrugBank: 25 drugs),   15 drug target genes,   90 drug target pathways]
Searched query = "Paroxysmal nocturnal hemoglobinuria", "PNH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 202 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-000646-20-IT
(EUCTR)		01/11/200423/12/2005TRIUMPH A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria PatientsTRIUMPH A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients paaroxysmal nocturnal hemoglobinuria
MedDRA version: 6.1;Level: PT;Classification code 10034042		Product Name: Eculizumab
INN or Proposed INN: VARI		ALEXION PHARMACEUTICALS INCNULLNot RecruitingFemale: yes
Male: yes		75Ireland;Italy;Sweden

274. Osteogenesis Imperfecta    [ 78 clinical trials,   87 drugs,   (DrugBank: 19 drugs),   14 drug target genes,   74 drug target pathways]
Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 78 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-005275-42-IT
(EUCTR)		21/03/200523/01/2008Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis ImperfectaStudy on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta Osteogenesis Imperfecta
MedDRA version: 6.1;Level: SOC;Classification code 10010331		Trade Name: GENOTROPIN*1TBF 5,3MG (16UI)
INN or Proposed INN: Somatropin
Trade Name: NERIXIA*INFUS IV CONC 2F 100MG
INN or Proposed INN: VARI		AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLNot RecruitingFemale: yes
Male: yes		Italy